Stimwave Technologies said late last week it won approval from the Australian Therapeutic Goods Administration for its Freedom spinal cord stimulation system, and launched the device in the country.

The Ft. Lauderdale-based company touts the Freedom SCS as the world’s 1st wireless, fully programmable neuromodulation device intended for treating chronic, intractable pain of the back or legs.

“This device unlocks so many more options for placement approaches and programming that were never possible before with wired systems. With the Freedom System, we are able to better detail each patient’s therapy and address their pain,” Stimwave co-founder & chair Laura Perryman said in a press release.

The device has also won clearance for use in the US, Canada and countries of the European Union, Stimwave said.

Last March, Stimwave Technologies said it launched its StimQ peripheral nerve stimulator in the US after winning pre-market approval from the FDA.

StimQ is powered by the same wearable patch technology that powers the Freedom-8A spinal cord stimulator, which won an FDA nod in December 2015.